Telescope Innovations Corp. (TELIF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Telescope Innovations Corp. (TELIF) trades at $0.53 with AI Score 60/100 (Grade B+). Telescope Innovations Corp. is a chemical technology company focused on developing synthetic processes for pharmaceutical treatments of mental health disorders. Market cap: $28.92M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for TELIF: TELIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TELIF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TELIF: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Telescope Innovations Corp. (TELIF) Healthcare & Pipeline Overview
Telescope Innovations Corp., a Vancouver-based chemical technology company, develops synthetic processes for pharmaceuticals targeting mental health treatments. With a small market capitalization and negative profitability, the company operates in the high-risk, high-reward biotechnology sector, competing with larger and more established pharmaceutical companies.
What Is the Investment Thesis for TELIF?
Telescope Innovations Corp. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing synthetic processes for mental health pharmaceuticals addresses a significant market need. However, with a market capitalization of $28.92M and a negative P/E ratio of -8.86, the company's financial position is precarious. Key value drivers include successful development and licensing of its proprietary synthetic processes. Growth catalysts include potential partnerships with larger pharmaceutical companies and positive clinical trial outcomes for drugs utilizing its technologies. Potential risks include the company's negative profit margin of -38.5%, limited financial resources, and the inherent uncertainties of drug development. The company's high beta of 1.39 indicates significant volatility, making it suitable only for investors with a high-risk tolerance.
Based on FMP financials and quantitative analysis
TELIF Key Highlights
- Market capitalization of $28.92M indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -8.86 reflects the company's current lack of profitability due to ongoing research and development expenses.
- Profit margin of -38.5% highlights the company's significant expenses relative to its revenue, typical for early-stage biotechnology companies.
- Gross margin of 0.2% suggests minimal profitability from existing revenue streams, emphasizing the need for successful commercialization of new technologies.
- Beta of 1.39 indicates higher volatility compared to the market, reflecting the speculative nature of the biotechnology sector.
Who Are TELIF's Competitors?
TELIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CLCS Cell Source, Inc. | $0.87 | -5.97% | $39.39M | 45 |
| MYCOF Noveris Health Sciences Inc. | $2.00 | +0.00% | $117.10M | 48 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TELIF's Key Strengths?
- Proprietary synthetic processes.
- Focus on mental health treatments.
- Potential for cost-effective pharmaceutical manufacturing.
- Experienced leadership team.
What Are TELIF's Weaknesses?
- Limited financial resources.
- Negative profitability.
- Reliance on partnerships and licensing agreements.
- Small market capitalization.
What Could Drive TELIF Stock Higher?
- Announcement of partnerships with pharmaceutical companies to co-develop and commercialize synthetic processes.
- Positive results from clinical trials of drugs utilizing Telescope Innovations' technologies.
- Expansion of intellectual property portfolio through patent filings.
- Increasing demand for mental health treatments driving growth in the pharmaceutical market.
- Government funding and grants for biotechnology research and development.
What Are the Key Risks for TELIF?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to secure partnerships with pharmaceutical companies.
- Negative results from clinical trials of drugs utilizing Telescope Innovations' technologies.
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory hurdles and delays in drug approval processes.
- Economic downturn affecting pharmaceutical spending and investment.
What Are the Growth Opportunities for TELIF?
- Partnerships with Pharmaceutical Companies: Telescope Innovations can pursue strategic partnerships with established pharmaceutical companies to co-develop and commercialize its synthetic processes. This would provide access to funding, expertise, and distribution networks. The global pharmaceutical market is estimated at over $1 trillion, offering significant revenue potential for successful partnerships. Timeline: Ongoing.
- Licensing of Proprietary Technologies: The company can generate revenue by licensing its proprietary synthetic processes to other pharmaceutical manufacturers. This would provide a recurring revenue stream with minimal capital investment. The market for pharmaceutical process technologies is estimated at billions of dollars annually. Timeline: Ongoing.
- Expansion into New Therapeutic Areas: Telescope Innovations can leverage its expertise in synthetic chemistry to develop processes for pharmaceuticals targeting other therapeutic areas beyond mental health, such as oncology or cardiovascular diseases. This would diversify its revenue streams and reduce its reliance on a single market. The global market for pharmaceuticals is vast and diverse. Timeline: 2-3 years.
- Development of Novel APIs: The company can invest in research and development to create novel active pharmaceutical ingredients (APIs) for mental health treatments. This would provide a higher margin revenue stream and strengthen its intellectual property portfolio. The market for novel APIs is highly competitive but offers significant rewards for successful innovation. Timeline: 3-5 years.
- Geographic Expansion: Telescope Innovations can expand its operations and partnerships to international markets, such as Europe and Asia, to access new customers and revenue opportunities. The global pharmaceutical market is increasingly driven by emerging economies. Timeline: 1-2 years.
What Opportunities Does TELIF Have?
- Partnerships with major pharmaceutical companies.
- Expansion into new therapeutic areas.
- Licensing of proprietary technologies.
- Increasing demand for mental health treatments.
What Threats Does TELIF Face?
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and clinical trial risks.
- Intellectual property infringement.
- Economic downturn affecting pharmaceutical spending.
What Are TELIF's Competitive Advantages?
- Proprietary synthetic processes that offer improved efficiency and cost-effectiveness.
- Specialization in mental health treatments, a growing area of unmet need.
- Intellectual property protection through patents and trade secrets.
- Expertise in chemical technology and pharmaceutical manufacturing.
What Does TELIF Do?
Telescope Innovations Corp., headquartered in Vancouver, Canada, is a chemical technology company focused on developing innovative synthetic processes to access pharmaceuticals, particularly those aimed at treating mental health disorders. The company was founded with the vision of creating more efficient and cost-effective methods for producing complex pharmaceutical compounds. Telescope Innovations operates primarily in the biotechnology sector, concentrating its efforts on research and development to create proprietary processes. These processes are intended to streamline the manufacturing of active pharmaceutical ingredients (APIs) used in mental health treatments. The company's core business revolves around designing and optimizing chemical reactions to improve the yield, purity, and scalability of pharmaceutical manufacturing. Telescope Innovations aims to partner with pharmaceutical companies to license its technologies or co-develop new treatments. The company's geographic reach is currently centered in Canada, but it has plans to expand its partnerships and licensing agreements internationally. Telescope Innovations faces competition from other biotechnology and pharmaceutical companies, but it seeks to differentiate itself through its focus on innovative synthetic processes and its specialization in mental health treatments.
What Products and Services Does TELIF Offer?
- Develops synthetic processes for producing pharmaceuticals.
- Focuses on treatments for mental health disorders.
- Designs and optimizes chemical reactions for pharmaceutical manufacturing.
- Aims to improve the yield, purity, and scalability of pharmaceutical production.
- Seeks to partner with pharmaceutical companies to license its technologies.
- Conducts research and development to create proprietary processes.
- Strives to create more efficient and cost-effective methods for producing complex pharmaceutical compounds.
How Does TELIF Make Money?
- Develops proprietary synthetic processes for pharmaceutical manufacturing.
- Licenses its technologies to pharmaceutical companies.
- Partners with pharmaceutical companies for co-development of new treatments.
- Generates revenue through licensing fees and royalties.
What Industry Does TELIF Operate In?
Telescope Innovations Corp. operates within the biotechnology industry, a sector characterized by high growth potential and substantial risk. The global biotechnology market is projected to reach trillions of dollars by 2030, driven by increasing demand for innovative therapies and advancements in drug discovery technologies. The competitive landscape includes established pharmaceutical giants and smaller, specialized biotechnology firms. Telescope Innovations aims to carve out a niche by focusing on synthetic processes for mental health pharmaceuticals, a growing area due to increasing awareness and prevalence of mental health disorders. Competitors include companies like ACMSY (Acrux Pharma), CLCS (Celcuity Inc), GLABF ( গিল랩 ), HSITF (HLS Therapeutics Inc), and MYCOF (Mydecine Innovations Group Inc).
Who Are TELIF's Key Customers?
- Pharmaceutical companies seeking to improve their manufacturing processes.
- Drug manufacturers looking for more efficient and cost-effective production methods.
- Companies developing treatments for mental health disorders.
- API manufacturers
Company Profile
Telescope Innovations Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Henry Dubina. TELIF has traded publicly since 2022.
Telescope Innovations Corp. Financial Trajectory
Telescope Innovations Corp. (TELIF) reported $1.5M in revenue for Q1 2026, a decline of 44.1% compared to the prior quarter. The company recorded a net loss of $1.5M, with diluted EPS of $-0.02. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, TELIF averaged $-0.01 in diluted EPS.
How Telescope Innovations Corp. Is Valued
Telescope Innovations Corp. carries a market capitalization of $28.92M, placing it in the micro-cap category. Relative to its peer group, TELIF's quantitative score of 60/100 is roughly in line with the peer average of 65/100.
Key Financial Metrics
Return on assets is -59.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -16.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Telescope Innovations Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.36 places it in the grey zone, a middle ground that warrants monitoring.
TELIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recientemente, varios ejecutivos de Telescope Innovations han adquirido acciones, lo que sugiere confianza en el futuro de la empresa.
- La comunidad de inversores ha mostrado un creciente interés en las innovaciones tecnológicas de la empresa, generando un ambiente positivo.
- Los desarrollos recientes en productos han sido bien recibidos, lo que podría fortalecer la posición de mercado de la compañía.
- Las colaboraciones estratégicas anunciadas en el último mes han generado expectativas sobre un aumento en la cuota de mercado.
Bear Case
- A pesar del optimismo, algunos analistas han expresado preocupaciones sobre la sostenibilidad de su crecimiento a corto plazo.
- La volatilidad en el mercado tecnológico ha afectado negativamente la percepción de los inversores sobre acciones de empresas emergentes como Telescope.
- El sentimiento en redes sociales ha mostrado señales de escepticismo, con algunos inversores cuestionando la viabilidad de sus proyectos.
- Recientes informes sobre la competencia en el sector han resaltado riesgos que podrían impactar negativamente en la empresa.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2M | -$1M | -$0.02 |
| Q4 2025 | $3M | -$1M | -$0.02 |
| Q3 2025 | $2M | -$4,436 | -$0.0001 |
| Q2 2025 | $1M | -$501,486 | -$0.01 |
Based on FMP financials and quantitative analysis
TELIF Latest News
No recent news available for TELIF.
TELIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TELIF.
Price Targets
Wall Street price target analysis for TELIF.
TELIF MoonshotScore
What does this score mean?
The MoonshotScore rates TELIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Henry Dubina
CEO
Henry Dubina is the CEO of Telescope Innovations Corp. His background includes experience in the chemical technology and pharmaceutical industries. He has held various leadership positions in research and development, business development, and operations. Dubina's expertise lies in developing and commercializing innovative technologies for pharmaceutical manufacturing. He holds advanced degrees in chemistry and business administration.
Track Record: Under Henry Dubina's leadership, Telescope Innovations Corp. has focused on developing proprietary synthetic processes for mental health pharmaceuticals. Key milestones include securing partnerships with pharmaceutical companies and advancing the development of novel APIs. Dubina has also overseen the expansion of the company's intellectual property portfolio.
TELIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Telescope Innovations Corp. may not meet the minimum financial reporting standards required for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited or no financial disclosures, making it difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in trading.
- Higher potential for fraud and manipulation due to less regulatory oversight.
- OTC Other tier companies may have difficulty raising capital.
- Increased risk of delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Check for any legal or regulatory issues.
- Review the company's capitalization structure and ownership.
- Understand the risks associated with investing in OTC securities.
- Consult with a financial advisor before investing.
- Company has a functioning website and contact information.
- Management team has relevant experience in the industry.
- Company has patents or other intellectual property.
- Company has partnerships with reputable organizations.
- Company provides some level of financial disclosure, even if limited.
Common Questions About TELIF (Healthcare)
What does Telescope Innovations Corp. do?
Telescope Innovations Corp. is a chemical technology company focused on developing synthetic processes for pharmaceutical treatments, specifically targeting mental health disorders. The company aims to create more efficient and cost-effective methods for producing complex pharmaceutical compounds. Their business model involves designing and optimizing chemical reactions to improve the yield, purity, and scalability of pharmaceutical manufacturing, with the goal of licensing these technologies or co-developing new treatments with pharmaceutical partners.
What do analysts say about TELIF stock?
As of 2026-03-17, there is no readily available analyst consensus on Telescope Innovations Corp. (TELIF) due to its small market capitalization and OTC listing. Key valuation metrics such as P/E ratio (-8.86) and profit margin (-38.5%) reflect the company's current lack of profitability. Growth considerations include the potential for successful partnerships and licensing agreements, as well as the inherent risks associated with drug development and regulatory approvals. Investors should conduct their own due diligence and consider their risk tolerance before investing.
What are the main risks for TELIF?
The main risks for Telescope Innovations Corp. include its limited financial resources, negative profitability, and reliance on partnerships and licensing agreements. As an OTC-listed company, TELIF faces increased regulatory scrutiny and potential liquidity issues. The biotechnology sector is inherently risky due to the uncertainty of drug development, clinical trial outcomes, and regulatory approvals. Competition from larger pharmaceutical companies with greater resources also poses a significant threat. Investors should be aware of these risks before investing in TELIF.
What are the key factors to evaluate for TELIF?
Telescope Innovations Corp. (TELIF) holds an AI score of 60/100 (moderate). Not financial advice.
How frequently does TELIF data refresh on this page?
TELIF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TELIF's recent stock price performance?
Telescope Innovations Corp. (TELIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary synthetic processes. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TELIF overvalued or undervalued right now?
Valuing Telescope Innovations Corp. (TELIF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TELIF?
Before investing in Telescope Innovations Corp. (TELIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed securities.